Citigroup
OBIO icon

Citigroup’s Orchestra BioMed OBIO Stock Holding History

Citigroup’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87K Sell
20,165
-5,364
-21% -$21.9K ﹤0.01% 4762
2026
Q1 		$108K Buy
25,529
+6,071
+31% +$25.8K ﹤0.01% 4250
2025
Q4 		$80.8K Buy
19,458
+19,417
+47,359% +$78.3K ﹤0.01% 4409
2025
Q3 		$102 Sell
41
-7,620
-99% -$21K ﹤0.01% 5809
2025
Q2 		$20.5K Sell
7,661
-9,557
-56% -$27.9K ﹤0.01% 5067
2025
Q1 		$73.7K Sell
17,218
-2,029
-11% -$10.1K ﹤0.01% 4752
2024
Q4 		$77K Buy
19,247
+2,397
+14% +$12.9K ﹤0.01% 4946
2024
Q3 		$86.6K Buy
16,850
+11,698
+227% +$76.4K ﹤0.01% 4824
2024
Q2 		$42K Buy
5,152
+2,749
+114% +$15.9K ﹤0.01% 4688
2024
Q1 		$12.7K Buy
2,403
+332
+16% +$2.25K ﹤0.01% 5150
2023
Q4 		$18.9K Buy
2,071
+2,069
+103,450% +$14.1K ﹤0.01% 5010
2023
Q3 		$17 Sell
2
-1,562
-100% -$10.5K ﹤0.01% 5590
2023
Q2 		$10.9K Buy
+1,564
New +$23.7K ﹤0.01% 5054

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Citigroup's OBIO Position: Q2 2026 in Review

Citigroup reduced its Orchestra BioMed (OBIO) stake by 21% in Q2 2026, selling an estimated $21.9K and leaving 20,165 shares worth $87K. The position accounts for ﹤0.01% of the portfolio, ranked #4762.

Citigroup first reported a position in OBIO in Q2 2023 and has held it in 13 quarters since. The position peaked at $108K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Citigroup held 20,165 shares of Orchestra BioMed worth $87K as of Q2 2026.
  • Citigroup sold 5,364 Orchestra BioMed shares in Q2 2026, an estimated $21.9K.
  • Orchestra BioMed made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4762 holding.
  • Citigroup first reported a position in Orchestra BioMed in Q2 2023 and has held it in 13 quarters since.
  • Citigroup's Orchestra BioMed position peaked at $108K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.